Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States
Sep 5, 2024Weston, Florida (September 4, 2024) – Apotex Corp., an affiliate of Apotex Inc. ("Apotex"), announced today the launch of dasatinib tablets, a generic version of Sprycel®1, in the United States, with 180-days of exclusivity.
Dasatinib is a kinase inhibitor used to treat certain types of leukemia in both adults and children 1 year of age and older, including cases where previous treatment were not effective or tolerated.
"Apotex continues to deliver best-in-class product launches, supporting patients on their journey to health,” said Christine Baeder, President, Apotex Corp. “As the first generic manufacturer to launch dasatinib in the United States, we are proud to provide this high-quality, cost-saving option."
Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions and contraindications.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceutical products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
-30-
1. Sprycel® is a registered trademark of Bristol-Myers Squibb Company.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Jul 17, 2026
Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
Toronto, ON, July 16, 2026. Apotex Health Corp ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.
-
Jul 8, 2026
Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection
Toronto, ON, July 8, 2026 – Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.